Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer

• Published in: World journal of gastrointestinal oncology 2018-12, Vol.10 (12), p.505-515
• Main Authors: Chung, Moon Jae, Kang, Huapyong, Kim, Ho Gak, Hyun, Jong Jin, Lee, Jun Kyu, Lee, Kwang Hyuck, Noh, Myung Hwan, Kang, Dae Hwan, Lee, Sang Hyub, Bang, Seungmin
• Format: Article
• Language: English
• Subjects: Clinical Trials Study
• ISSN: 1948-5204; 1948-5204
• DOI: 10.4251/wjgo.v10.i12.505

To evaluate the efficacy and safety of modified FOLFIRINOX as a second-line treatment for gemcitabine (GEM)-refractory unresectable pancreatic cancer (PC). This study was a prospective, multicenter, one-arm, open-label, phase II trial. Patients with unresectable PC, who showed disease progression during GEM-based chemotherapy were enrolled. All patients were administered FOLFIRINOX with reduced irinotecan and oxaliplatin (RIO; irinotecan 120 mg/m and oxaliplatin 60 mg/m ), which was set according to the phase I study of FOLFIRINOX. The objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), adverse events were evaluated. Additionally, changes in quality of life (QoL) were assessed using a questionnaire on QoL. Between August 2015 and May 2016, a total of 48 patients were enrolled. The median follow-up time was 259 d with a median of 8.5 cycles. The ORR and DCR were 18.8% and 62.5%, respectively, including one patient who showed complete remission. The median PFS was 5.8 mo [95% confidence interval (CI): 3.7-7.9] and median OS was 9.0 mo (95%CI: 6.4-11.6). Neutropenia (64.6%) was the most common grade 3-4 adverse event, followed by febrile neutropenia (16.7%). Although 14.6% of patients experienced grade 3 fatigue, most non-hematologic AEs were under grade 2. In the QoL analysis, the global health status score before treatment was not different from the score at the last visit after treatment (45.43 ± 22.88 48.66 ± 24.14, = 0.548). FOLFIRINOX with RIO showed acceptable toxicity and promising efficacy for GEM-refractory unresectable PC. However, this treatment requires careful observation of treatment-related hematologic toxicities.